ascendis transcon glp-1 program Pharma announced that the U.S. Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide, PTH,) injection as the First and Only treatment for adults with hyperparathyroidism. Palopegteriparatide is a prodrug It Is a Huge Market.
Pay in 4 interest-free payments of $6.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18





























